Table 1 Baseline clinical characteristics
Variable | Study groups | P-value | |||
|---|---|---|---|---|---|
Placebo (n = 17) | 600 IU/day (n = 17) | 2000 IU/day (n = 18) | 4000 IU/day (n = 18) | ||
Age (years) | 27.78 ± 2.6 | 26.19 ± 2.5 | 24.38 ± 2.0 | 25.51 ± 2.2 | 0.77 |
Male/Femalea | 4/12 | 2/13 | 3/14 | 2/15 | 0.76 |
Height (cm) | 164.28 ± 2.1 | 164.60 ± 2.0 | 163.84 ± 2.4 | 164.20 ± 1.7 | 0.99 |
Weight (kg) | 98.42 ± 6.7 | 93.39 ± 3.7 | 99.16 ± 5.0 | 92.77 ± 4.8 | 0.74 |
BMI (kg/m2) | 36.19 ± 2.0 | 34.56 ± 1.4 | 37.08 ± 1.9 | 34.42 ± 1.7 | 0.66 |
Serum 25(OH)D (ng/mL) | 15.88 ± 1.4 | 14.00 ± 0.8 | 15.93 ± 1.0 | 13.25 ± 1.0 | 0.21 |
Plasma iPTH (pg/mL)# | 47.32 ± 3.6 | 59.60 ± 7.8 | 50.60 ± 4.2 | 62.00 ± 8.8 | 0.32 |
Plasma 1,25(OH)2D (pg/mL) | 34.04 ± 1.9 | 37.40 ± 1.8 | 35.18 ± 2.3 | 32.70 ± 1.1 | 0.46 |
Plasma FGF-23 (pg/mL)# | 6.53 ± 0.9 | 6.92 ± 0.8 | 8.57 ± 1.6 | 6.57 ± 0.9 | 0.81 |
Plasma Phosphorus (mg/dL)# | 3.74 ± 0.2 | 4.01 ± 0.3 | 3.61 ± 0.1 | 3.80 ± 0.1 | 0.71 |
Urine Ca/Cr ratio | 0.08 ± 0.05 | 0.05 ± 0.03 | 0.10 ± 0.05 | 0.08 ± 0.05 | 0.09 |